Navigation Links
Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
Date:10/30/2008

l milestones expected to be reached by the third quarter of 2009.

Through its IDDP program, JDRF has funded some 25 companies, representing approximately $29 million in diabetes science.

"Our partnership with Bayhill Therapeutics reflects JDRF's commitment to accelerating the pace of science leading to a cure for type 1 diabetes," said Dr. Richard A. Insel, JDRF Executive Vice President, Research. "Bayhill's DNA vaccine protocol has the potential to negate the autoimmune process causing type 1 diabetes, which must be addressed to cure the disease."

About T1D

Type 1 diabetes is an autoimmune disease that results from the immune system attacking and destroying insulin-producing cells in the pancreas. It affects children, adolescents, and adults, and last for life. Tight control of blood glucose is critical to both the long- and short-term health of patients. Short-term effects of poor glucose control include diabetic ketoacidosis, which is a condition that can lead to coma. Long-term effects include elevated glucose levels, blindness, kidney disease, heart disease, peripheral vascular disease and stroke. In order to keep blood glucose at or near normal levels, patients require the life-long administration of insulin, which is the only approved therapy for type 1 diabetes.

About BHT-3021

BHT-3021 is a plasmid encoding proinsulin designed to tolerize the immune system, thereby turning off the self directed immune attack against the islet cells. This product candidate's potential to stabilize or improve glucose control by eliminating the autoimmune response could lead to reduced insulin dependence and long-term complications of type 1 diabetes.

Patient enrollment is currently underway in a Phase I/II placebo-controlled clinical trial of BHT-3021 to evaluate safety, pharmacodynamics, immune tolerance and pancreatic function in patients with T1D. Preliminary data from the trial have been pos
'/>"/>

Contact: Leslie Schwartz
lschwartz@jdrf.org
212-479-7553
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
2. Michael J. Fox Foundation PD Therapeutics Conference
3. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
4. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
5. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
6. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
7. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
8. Gender, coupled with diabetes, affects vascular disease development
9. Breakthrough research identifies how cells from pigs may cure diabetes
10. Botched production of insulin molecule may lead to diabetes
11. Joslin researchers uncover potential role of leptin in diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
(Date:7/9/2014)... receptor antagonists can alleviate the symptoms of ... cognitive dysfunction and effectively scavenge amyloid beta ... (Aβ) vaccines reduced and eliminated Aβ deposition ... model, and significantly improved behavioral and cognitive ... First Affiliated Hospital of China Medical University, ...
(Date:7/9/2014)... inhabitants of the sea: tiny haptophytes of the type ... eye, when they are in bloom in spring, they ... on satellite images. "Together with other phytoplankton, Emiliania ... global photosynthesis output," states Prof. Dr. Georg Pohnert of ... the greenhouse gas carbon dioxide CO2 is ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Short circuit in the food web 2
... tropical parasitic disease that can lead to life-threatening heart ... than previously thought, according to research from The University ... for four years now, and this year the number ... professor of integrative biology and philosophy at The University ...
... Cincinnati, OH, October 6, 2011 -- Directly advertising food ... providers, and the American Academy of Pediatrics and the ... impact of advertising on children,s healthy food choices. ... Journal of Pediatrics explores the relationship between ...
... can ever know about long-gone creatures is what they ... resurrect actual specimens and compare their features with their ... Toronto biologists helping to create a seed bank that ... allowing them to measure evolution caused by global change. ...
Cached Biology News:Chagas disease may be a threat in South Texas, says researcher 2Study suggests children's food choices are affected by direct advertising and parental influence 2Seed time-capsule will aid study of plant evolution amid environmental change 2
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Calif., July 22 CV Therapeutics,Inc. (Nasdaq: CVTX ... results for 2008 after the market closes on Thursday, ... at 5:00 p.m. EDT,2:00 p.m. PDT, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... is bringing aboard Ashton S. Maaraba, a key Pharmacy, Pharmacy Services ... , ... (PRWEB) July 22, 2008 -- PharmaSmart International ... Ashton S. Maaraba, a key Pharmacy, Pharmacy Services & HBC industry ...
... U.S. Department of Energy,s Lawrence Berkeley National Laboratory (Berkeley ... performed the first scanning tunneling spectroscopy of graphene flakes ... latest in a series of surprising insights into the ... carbon: an unexpected gap-like feature in the energy spectrum ...
Cached Biology Technology:CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 2A phonon floodgate in monolayer carbon 2A phonon floodgate in monolayer carbon 3A phonon floodgate in monolayer carbon 4A phonon floodgate in monolayer carbon 5